| Literature DB >> 27797804 |
Yisi D Ji1, Ali Aboalela2, Alessandro Villa3.
Abstract
Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus. 2016 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27797804 PMCID: PMC5073606 DOI: 10.1136/bcr-2016-217513
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X